Institutional Investors Urged to Evaluate Lead Plaintiff Opportunities in Mereo BioPharma Securities Litigation

Mereo BioPharma Group plc is facing a securities class action alleging misrepresentations about its Phase 3 clinical trial program for setrusumab. Institutional investors who purchased MREO ADS during the Class Period may have significant losses and are eligible to participate in the litigation. Lead plaintiffs direct the litigation and select counsel on behalf of the class. There is no cost to participate and recovery is typically funded through contingency fee arrangements.